REFERENCES
1. Grunewald TGP, Cidre-Aranaz F, Surdez D, et al. Ewing sarcoma. Nat
Rev Dis Primers 2018:4(1):5.
2. Ladenstein R, Potschger U, Le Deley MC, et al. Primary disseminated
multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin
Oncol 2010:28(20):3284-3291.
3. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in
Ewing’s tumor of bone: analysis of 975 patients from the European
Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol
2000:18(17):3108-3114.
4. Thiel U, Wawer A, von Luettichau I, et al. Bone marrow involvement
identifies a subgroup of advanced Ewing sarcoma patients with fatal
outcome irrespective of therapy in contrast to curable patients with
multiple bone metastases but unaffected marrow. Oncotarget
2016:7(43):70959-70968.
5. Gaspar N, Hawkins DS, Dirksen U, et al. Ewing Sarcoma: Current
Management and Future Approaches Through Collaboration. J Clin Oncol
2015:33(27):3036-3046.
6. Biermann JS, Chow W, Reed DR, et al. NCCN Guidelines Insights: Bone
Cancer, Version 2.2017. J Natl Compr Canc Netw 2017:15(2):155-167.
7. Bain BJ. Bone marrow biopsy morbidity: review of 2003. J Clin Pathol
2005:58(4):406-408.
8. Mody RJ, Bui C, Hutchinson RJ, et al. FDG PET imaging of childhood
sarcomas. Pediatr Blood Cancer 2010:54(2):222-227.
9. Behzadi AH, Raza SI, Carrino JA, et al. Applications of PET/CT and
PET/MR Imaging in Primary Bone Malignancies. PET Clin
2018:13(4):623-634.
10. Guimaraes JB, Rigo L, Lewin F, et al. The importance of PET/CT in
the evaluation of patients with Ewing tumors. Radiol Bras
2015:48(3):175-180.
11. Anderson PM. Futility versus utility of marrow assessment in initial
Ewing sarcoma staging workup. Pediatr Blood Cancer 2015:62(1):1-2.
12. Balamuth NJ, Womer RB. Ewing’s sarcoma. Lancet Oncol
2010:11(2):184-192.
13. Volker T, Denecke T, Steffen I, et al. Positron emission tomography
for staging of pediatric sarcoma patients: results of a prospective
multicenter trial. J Clin Oncol 2007:25(34):5435-5441.
14. Kumar J, Seith A, Kumar A, et al. Whole-body MR imaging with the use
of parallel imaging for detection of skeletal metastases in pediatric
patients with small-cell neoplasms: comparison with skeletal
scintigraphy and FDG PET/CT. Pediatr Radiol 2008:38(9):953-962.
15. Kneisl JS, Patt JC, Johnson JC, et al. Is PET useful in detecting
occult nonpulmonary metastases in pediatric bone sarcomas? Clin Orthop
Relat Res 2006:450:101-104.
16. Gyorke T, Zajic T, Lange A, et al. Impact of FDG PET for staging of
Ewing sarcomas and primitive neuroectodermal tumours. Nucl Med Commun
2006:27(1):17-24.
17. Franzius C, Sciuk J, Daldrup-Link HE, et al. FDG-PET for detection
of osseous metastases from malignant primary bone tumours: comparison
with bone scintigraphy. Eur J Nucl Med 2000:27(9):1305-1311.
18. Harrison DJ, Parisi MT, Shulkin BL. The Role of (18)F-FDG-PET/CT in
Pediatric Sarcoma. Semin Nucl Med 2017:47(3):229-241.
19. Eugene T, Corradini N, Carlier T, et al. (1)(8)F-FDG-PET/CT in
initial staging and assessment of early response to chemotherapy of
pediatric rhabdomyosarcomas. Nucl Med Commun 2012:33(10):1089-1095.
20. Treglia G, Salsano M, Stefanelli A, et al. Diagnostic accuracy of
(1)(8)F-FDG-PET and PET/CT in patients with Ewing sarcoma family
tumours: a systematic review and a meta-analysis. Skeletal Radiol
2012:41(3):249-256.
21. Newman EN, Jones RL, Hawkins DS. An evaluation of
[F-18]-fluorodeoxy-D-glucose positron emission tomography, bone
scan, and bone marrow aspiration/biopsy as staging investigations in
Ewing sarcoma. Pediatr Blood Cancer 2013:60(7):1113-1117.
22. Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging
for detection of bone metastases in children and young adults:
comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol
2001:177(1):229-236.
23. Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92
Study: two randomized trials of Ewing’s sarcoma
treatment–cyclophosphamide compared with ifosfamide in standard-risk
patients and assessment of benefit of etoposide added to standard
treatment in high-risk patients. J Clin Oncol 2008:26(27):4385-4393.
24. Cesari M, Righi A, Colangeli M, et al. Bone marrow biopsy in the
initial staging of Ewing sarcoma: Experience from a single institution.
Pediatr Blood Cancer 2019:66(6):e27653.
25. Khan SJ, Ishaq I, Saeed H, et al. Bone Marrow Involvement in
Metastatic Pediatric Ewing Sarcoma. J Coll Physicians Surg Pak
2017:27(8):502-504.
26. Kopp LM, Hu C, Rozo B, et al. Utility of bone marrow aspiration and
biopsy in initial staging of Ewing sarcoma. Pediatr Blood Cancer
2015:62(1):12-15.
27. Oberlin O, Bayle C, Hartmann O, et al. Incidence of bone marrow
involvement in Ewing’s sarcoma: value of extensive investigation of the
bone marrow. Med Pediatr Oncol 1995:24(6):343-346.
28. Wexler LH, DeLaney TF, Tsokos M, et al. Ifosfamide and etoposide
plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed
Ewing’s sarcoma family of tumors. Cancer 1996:78(4):901-911.
29. Inagaki C, Shimoi T, Sumiyoshi Okuma H, et al. Bone marrow
examination in patients with Ewing sarcoma/peripheral primitive
neuroectodermal tumor without metastasis based on
(18)F-fluorodeoxyglucose positron emission tomography/computed
tomography. Med Oncol 2019:36(7):58.
30. Kasalak O, Glaudemans A, Overbosch J, et al. Can FDG-PET/CT replace
blind bone marrow biopsy of the posterior iliac crest in Ewing sarcoma?
Skeletal Radiol 2018:47(3):363-367.
31. Albano D, Dondi F, Schumacher RF, et al. Clinical and Prognostic
Role of 18F-FDG PET/CT in Pediatric Ewing Sarcoma. J Pediatr Hematol
Oncol 2020:42(2):e79-e86.
32. Cangir A, Vietti TJ, Gehan EA, et al. Ewing’s sarcoma metastatic at
diagnosis. Results and comparisons of two intergroup Ewing’s sarcoma
studies. Cancer 1990:66(5):887-893.
33. Worch J, Ranft A, DuBois SG, et al. Age dependency of primary tumor
sites and metastases in patients with Ewing sarcoma. Pediatr Blood
Cancer 2018:65(9):e27251.
34. Vietti TJ, Gehan EA, Nesbit ME, Jr., et al. Multimodal therapy in
metastatic Ewing’s sarcoma: an Intergroup Study. Natl Cancer Inst Monogr
1981(56):279-284.
35. Oberlin O, Rey A, Desfachelles AS, et al. Impact of high-dose
busulfan plus melphalan as consolidation in metastatic Ewing tumors: a
study by the Societe Francaise des Cancers de l’Enfant. J Clin Oncol
2006:24(24):3997-4002.
36. Bernstein ML, Devidas M, Lafreniere D, et al. Intensive therapy with
growth factor support for patients with Ewing tumor metastatic at
diagnosis: Pediatric Oncology Group/Children’s Cancer Group Phase II
Study 9457–a report from the Children’s Oncology Group. J Clin Oncol
2006:24(1):152-159.
37. Miser JS, Goldsby RE, Chen Z, et al. Treatment of metastatic Ewing
sarcoma/primitive neuroectodermal tumor of bone: evaluation of
increasing the dose intensity of chemotherapy–a report from the
Children’s Oncology Group. Pediatr Blood Cancer 2007:49(7):894-900.
38. Kasalak O, Dammann A, Adams HJA, et al. Surveillance MRI for the
detection of locally recurrent Ewing sarcoma seems futile. Skeletal
Radiol 2018:47(11):1517-1522.
39. Yagci-Kupeli B, Kocyigit-Deveci E, Adamhasan F, et al. The Value of
18F-FDG PET/CT in Detecting Bone Marrow Involvement in Childhood
Cancers. J Pediatr Hematol Oncol 2019:41(6):438-441.
40. Wang J, Weiss LM, Chang KL, et al. Diagnostic utility of bilateral
bone marrow examination: significance of morphologic and ancillary
technique study in malignancy. Cancer 2002:94(5):1522-1531.